Compugen logo

CompugenNASDAQ: CGEN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

11 August 2000

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$131.62 M
-67%vs. 3y high
48%vs. sector
-30%vs. 3y high
78%vs. sector
-49%vs. 3y high
60%vs. sector
-95%vs. 3y high
40%vs. sector

Price

pre-market | Thu, 21 Nov 2024 09:26:02 GMT
$1.47+$0.01(+0.73%)

Dividend

No data over the past 3 years
$17.13 M$24.96 M
$17.13 M$1.28 M

Analysts recommendations

Institutional Ownership

CGEN Latest News

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
seekingalpha.com12 November 2024 Sentiment: NEUTRAL

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants Stephen Willey - Stifel Daina Graybosch - Leerink Partners Tony Butler - Rodman and Renshaw Asthika Goonewardene - Truist Securities Operator Ladies and gentlemen, thank you for joining us today.

Compugen Reports Third Quarter 2024 Results
prnewswire.com12 November 2024 Sentiment: POSITIVE

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunity On track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024 Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024 and advanced rilvegostomig into two additional Phase 3 lung cancer trials Solid balance sheet with expected cash runway into 2027 anticipated to reach potential key catalysts, including projected COM701 sub-study 1 interim analysis and support advancement of COM503 in the clinic HOLON, Israel , Nov. 12, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.

Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
zacks.com12 November 2024 Sentiment: NEGATIVE

Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago.

Compugen to Participate in Stifel 2024 Healthcare Conference
prnewswire.com11 November 2024 Sentiment: POSITIVE

HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City.

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
prnewswire.com29 October 2024 Sentiment: POSITIVE

HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open.

Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
zacks.com24 October 2024 Sentiment: POSITIVE

On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.

Compugen to Present at Single Cell Genomics 2024 Conference
prnewswire.com09 September 2024 Sentiment: NEUTRAL

HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
prnewswire.com29 August 2024 Sentiment: POSITIVE

HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.

Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
zacks.com26 August 2024 Sentiment: POSITIVE

Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.

  • 1(current)
  • 2

What type of business is Compugen?

Compugen Ltd. is an Israeli company specializing in therapeutic discoveries and developments. It was registered in Israel in 1993. The company's main focus is on discovering new drugs and developing therapeutic agents in the field of cancer immunotherapy. The innovative immuno-oncology program consists of three clinical-stage programs targeting immune checkpoints: COM701, BAY 1905254, and COM902. COM701 is a first-in-class antibody for the treatment of solid tumors, being clinically developed in collaboration with BMS (Bristol-Myers Squibb). BAY 1905254 has demonstrated anti-tumor activity as a monotherapy, and it also has additional anti-tumor activity in combination with other cancer therapy approaches, indicating the possibility of multiple combined uses in cancer immunotherapy. COM902 is a therapeutic antibody being developed for patients with advanced malignant neoplasms.

What sector is Compugen in?

Compugen is in the Healthcare sector

What industry is Compugen in?

Compugen is in the Biotechnology industry

What country is Compugen from?

Compugen is headquartered in Israel

When did Compugen go public?

Compugen initial public offering (IPO) was on 11 August 2000

What is Compugen website?

https://cgen.com

Is Compugen in the S&P 500?

No, Compugen is not included in the S&P 500 index

Is Compugen in the NASDAQ 100?

No, Compugen is not included in the NASDAQ 100 index

Is Compugen in the Dow Jones?

No, Compugen is not included in the Dow Jones index

When was Compugen the previous earnings report?

No data

When does Compugen earnings report?

The next expected earnings date for Compugen is 05 March 2025